Press Releases
2024
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2023
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2022
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2021
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2020
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2019
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2018 & Prior
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Media
A next-gen vaccine that could help end COVID-19 whack-a-mole
EpicentRx used its AdAPT Platform to develop a nucleocapsid-based next-gen COVID 19 vaccine candidate and is ready for clinical trials. CEO Dr. Tony Reid recently discussed with Drug Discovery & Development.
A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC)
Next-generation SARS-CoV-2 nucleocapsid-based vaccines may provide optimal protection against infection
Neuroendocrine Tumors Market to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies – EpicentRx, Pfizer, Ignyta, Amgen, Progenics Pharma, Hutchison MediPharma, and Others
Clinical Catch-Up: COVID-19 Updates from Sinovac, Moderna, Arcturus, Novavax and More
EpicentRx begins Phase I trial of paediatric CNS tumour treatment
Several Players Begin 2022 with New Partnerships in Place
BioSpace
Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRPα Immunotherapy
BioSpace
Epigenetic Therapies Start Operating Outside the Lines
Genetic Engineering and Biotechnology News
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development
AdAPT-001 Mechanism of Action
AdAPT-001 doesn’t just create a cancer-targeted infection, it produces a proprietary TGFβ “trap”...
Conferences
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
The recent backdrop of the very polarizing US Presidential election serves as the central analogy for an EpicentRx-authored article about macrophages in the December edition of PharmaTimes. Read more here and cast your vote on this well-written article entitled “Outside the Box”:…